AMLX
$14.33-0.05 (-0.35%)
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigation...
Recent News
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf.
Amylyx Pharmaceuticals (NASDAQ:AMLX) co-CEO Justin Klee discussed the company’s lead endocrine program, avexitide, and provided updates on its pivotal LUCIDITY trial during a conversation at day two of the Leerink Partners Conference. Avexitide mechanism and the unmet need in post-bariatric hypogly
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Amylyx Pharmaceuticals Inc (AMLX) extends its cash runway into 2028 while navigating clinical trial complexities and market opportunities.
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress
Amylyx Pharmaceuticals (AMLX) shares are reacting to fresh Q4 and full year 2025 results, where the company reported a smaller net loss and noted progress across its late stage clinical pipeline. See our latest analysis for Amylyx Pharmaceuticals. Even with the 1 day share price return of 7.78% decline taking the stock to US$14.11, Amylyx still has a year to date share price return of 23.56%. The 1 year total shareholder return of about 4.7x and 3 year total shareholder return of 60.72%...
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout
Amylyx Pharmaceuticals (NASDAQ:AMLX) executives outlined a slate of milestones they expect to shape the company’s near-term trajectory during TD Cowen’s 46th Annual Healthcare Conference, with co-CEOs Josh Cohen and Justin Klee emphasizing that 2026 could be “transformative” primarily due to a pivot
Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes
Amylyx Pharmaceuticals has completed recruitment for its pivotal Phase 3 LUCIDITY trial of Avexatide for post bariatric hypoglycemia. The company is shifting its core focus toward Avexatide while preparing for a potential expedited regulatory submission once top line data are available later this year. Amylyx has also nominated AMX318, a GLP 1 antagonist, as a new development candidate and is refining its broader pipeline. Amylyx Pharmaceuticals (NasdaqGS:AMLX) is drawing attention as the...